Lee M. Techner

Evaluation of TU-100 (Daikenchuto), a Traditional Japanese Kampo Medicine, as an Adjunct to Enhanced Recovery After Surgery, for Acceleration of Gastrointestinal Recovery After Bowel Resection: Results of a Proof-of-Concept, Phase 2, Randomized, Double-Blinded, Placebo-Controlled Trial

Srdjan S. Nedeljković, Jennifer D Silinsky, Deborah A. Nagle, Sang W. Lee et autres

BACKGROUND: A transient inhibition of GI motility (postoperative ileus) can occur after colorectal surgery and may lead to complications and prolonged hospitalization. OBJECTIVE: To examine the effect of TU-100, a Japanese herbal medicine, on the acceleration of GI recovery after bowel resection. …

us, jp (code pays fourni par la source)

Alvimopan Accelerates Gastrointestinal Recovery After Radical Cystectomy: A Multicenter Randomized Placebo-Controlled Trial

Cheryl T. Lee, Sam S. Chang, Ashish M. Kamat, Gilad E. Amiel et autres

us, ru (code pays fourni par la source)

Alvimopan, a Peripherally Acting μ-Opioid Receptor Antagonist, is Associated with Reduced Costs after Radical Cystectomy: Economic Analysis of a Phase 4 Randomized, Controlled Trial

Teresa L. Kauf, Robert Scott Svatek, Gilad E. Amiel, Timothy L. Beard et autres

PURPOSE: We evaluated the effect of alvimopan treatment vs placebo on health care utilization and costs related to gastrointestinal recovery in patients treated with radical cystectomy in a randomized, phase 4 clinical trial. MATERIALS AND METHODS: Resource utilization data were prospectively collected …

us (code pays fourni par la source)

1870 ALVIMOPAN, A PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONIST, ACCELERATES GASTROINTESTINAL RECOVERY AND DECREASES LENGTH OF HOSPITAL STAY AFTER RADICAL CYSTECTOMY

Ashish M. Kamat, Sam S. Chang, Cheryl Yi‐Pin Lee, Gilad E. Amiel et autres

You have accessJournal of UrologyBladder Cancer: Metastatic Disease + Staging1 Apr 20131870 ALVIMOPAN, A PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONIST, ACCELERATES GASTROINTESTINAL RECOVERY AND DECREASES LENGTH OF HOSPITAL STAY AFTER RADICAL CYSTECTOMY Ashish M Kamat, Sam S Chang, Cheryl Lee, Gilad Amiel, Timothy …

us (code pays fourni par la source)

Economic Analysis of Alvimopan—A Clarification and Commentary

TIMOTHY J. BELL, Sara A. Poston, Michael D. Kraft, Anthony J. Senagore et autres

Peer Reviewed

us (code pays fourni par la source)

Alvimopan for acceleration of GI recovery after bowel resection.

Sally Russell, Brad J. Champagne, Lee M. Techner

Nurses play a critical role in the management of postoperative ileus during the perioperative phase of recovery. Alvimopan is an oral, peripherally acting, mu-opioid receptor antagonist that accelerates time to gastrointestinal recovery (resolution of postoperative ileus), representing a potential advance in management …

Mo2084 CB-5945 0.25 mg Twice Daily Is Associated With Significantly Increased Spontaneous Bowel Movement and Greater Proportion of Responders Compared With Placebo in Patients on Chronic Opioid Therapy for Noncancer Pain (45CL242; NCT01207427)

Neil Singla, Lee M. Techner, Kathie Gabriel, Richard M. Mangano

ADL5945, a potent orally bioavailable peripheral opioid receptor antagonist, improves bowel motility w/a low incidence/severity of GI AEs in a dose-dependent manner: results of 2 Ph 2 trials in opioid-induced constipation pts (45CL242 and 45CL243)

Lee M. Techner, Neil Singla, Katherin A. Gabriel, Richard M. Mangano

us (code pays fourni par la source)

Evaluation of Clinical Outcomes With Alvimopan in Clinical Practice

Conor Patrick Delaney, Christopher Craver, Melinda Maggard Gibbons, Amy W. Rachfal et autres

OBJECTIVE: To evaluate in-hospital clinical outcomes after open and laparoscopic bowel resection (BR) with or without alvimopan treatment. BACKGROUND: Delayed return of gastrointestinal function after BR may be associated with greater postoperative morbidity and increased hospital length of stay (LOS). In clinical …

us, nl (code pays fourni par la source)

Impact of alvimopan (entereg) on hospital costs after bowel resection: results from a large inpatient database.

Sara A. Poston, Michael Samuel Broder, Melinda Maggard Gibbons, Robert MacLaren et autres

PURPOSE: Delayed gastrointestinal (GI) recovery after bowel resection is associated with longer hospital stays and increased health care costs. Alvimopan (Entereg), a peripherally acting mu-opioid receptor antagonist, accelerates GI recovery after bowel-resection surgery. We undertook a study to evaluate the economic impact …

Alvimopan for the Management of Postoperative Ileus After Bowel Resection: Characterization of Clinical Benefit by Pooled Responder Analysis

KIRK A. LUDWIG, Eugene R. Viscusi, Bruce G. Wolff, Conor Patrick Delaney et autres

BACKGROUND: A pooled post hoc responder analysis was performed to assess the clinical benefit of alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist, for the management of postoperative ileus after bowel resection. METHODS: Adult patients who underwent laparotomy for bowel resection scheduled …

us (code pays fourni par la source)

On “Pathogenesis and Management of Postoperative Ileus” (Clin Colon Rectal Surg 2009;22:47–50)

Lee M. Techner

I read with great interest the article in your Volume 22 issue by Carroll and Alavi regarding the pathogenesis and management of postoperative ileus (POI).[ 1 ] Alvimopan was reviewed by the authors and concluded to show “promise in reducing POI, but …

us (code pays fourni par la source)